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paaR2–paaA2–parE2 is a three-component toxin–antitoxin module found in
prophage CP-993P of Escherichia coli O157:H7. Transcription regulation of this
module occurs via the 123-amino-acid regulator PaaR2, which forms a large
oligomeric structure. Despite appearing to be well folded, PaaR2 withstands
crystallization, as does its N-terminal DNA-binding domain. Native mass
spectrometry was used to screen for nanobodies that form a unique complex and
stabilize the octameric structure of PaaR2. One such nanobody, Nb33, allowed
crystallization of the protein. The resulting crystals belong to space group F432,
with unit-cell parameter a = 317 Å, diffract to 4.0 Å resolution and are likely to
contain four PaaR2 monomers and four nanobody monomers in the asymmetric
unit. Crystals of two truncates containing the N-terminal helix–turn–helix
domain also interact with Nb33, and the corresponding co-crystals diffracted to
1.6 and 1.75 Å resolution.
1. Introduction
X-ray crystallography, as witnessed by the more than 120 000
entries in the Protein Data Bank (Berman et al., 2000),
remains one of the most important methods in structural
biology. Advances in technology and methodology for data
collection and structure determination allow more and more
complex and large macromolecular assemblies to be tackled.
While it is often assumed that any pure, stable and well
folded protein can be crystallized, this step often remains the
greatest bottleneck in modern X-ray structure determination
(Holcomb et al., 2017). A typical crystallographic study starts
with overexpression and purification of the target molecule,
followed by testing the protein using one or more commercial
crystallization screens. In the case of success, the crystals are
further optimized if necessary. In the case of failure, alter-
native purification protocols, expression strategies or constructs
need to be designed.
Several techniques have been developed to enhance success
in crystallization and crystal optimization. These include the
screening of additives, the modification of surface residues,
either chemically (Goldschmidt et al., 2014; Derewenda &
Vekilov, 2006; Schubot & Waugh, 2004) or via site-specific
mutagenesis (Ruggiero et al., 2012; Roos et al., 2006),
(heterologous) seeding techniques and the removal of flexible
regions through limited proteolysis (Tong et al., 2014).
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An interesting approach to tackle difficult targets is the use
of crystallization chaperones: proteins that increase the crys-
tallization probability of the target by binding to it with high
affinity, thereby stabilizing its structure and/or conformation
and hence providing a different surface that may be involved
in crystal lattice interactions (Koide, 2009). Originally, anti-
body fragments such as Fab or Fv were used to facilitate the
crystallization of membrane proteins (Hunte & Michel, 2002;
Uysal et al., 2009; Stahl et al., 2014). Because of the inherent
difficulties with the production of Fab and Fv fragments,
several alternatives have been explored. So-called designed
ankyrin-repeat proteins (DARPins) have been documented to
be useful crystallization chaperones (Sennhauser & Grütter,
2008). The wide diversity in unique structural features of
antibodies (or fragments thereof) from various organisms has
also provided the crystallographic community with useful
tools (de Los Rios et al., 2015).
So-called nanobodies (or VHH antibodies) are single-
domain VH fragments from camelid heavy-chain-only
antibodies (Hamers-Casterman et al., 1993). In contrast to
fragments from classic antibodies, nanobodies can be
expressed with high yields and are very soluble (Muyldermans,
2001). They also show good thermodynamic stability
(Dumoulin et al., 2002) and are able to target epitopes that are
difficult for classical antibodies, in particular deep clefts
(Desmyter et al., 1996). Nanobodies have been shown to be
very suitable as crystallization chaperones. They can stabilize
dynamic proteins and allow easier crystallization by masking
flexible regions, as was first employed for the Escherichia coli
antitoxin MazE (Loris et al., 2003) and subsequently for other
proteins with flexible regions (Koide, 2009; Korotkov et al.,
2009). Their high specificity also allows them to stabilize
specific conformations in multi-domain proteins (Rasmussen,
Choi et al., 2011; Huang et al., 2015) and to stabilize macro-
molecular complexes (Rasmussen, DeVree et al., 2011; Bara-
nova et al., 2012).
PaaR2 is a 123-amino-acid transcription regulator encoded
in the paaR2–paaA2–parE2 operon that is present within
prophage CP-993P in the genome of E. coli O157:H7 (Hallez
et al., 2010). It consists of a predicted helix–turn–helix (HTH)
domain followed by a predicted coiled-coil domain (De Bruyn
et al., 2019), and a BLAST search revealed that the protein
shows weak sequence similarity (14% sequence identity) to
residues 14–135 of the C2 repressor of Salmonella bacterio-
phage P22. The other two proteins encoded in the operon,
ParE2 and PaaA2, form a type II toxin–antitoxin module
where the toxin ParE2 acts on an as yet unidentified target.
The antitoxin PaaA2 is an intrinsically disordered protein
(Sterckx et al., 2014) that wraps around ParE2, resulting in the
formation of a heterohexadecameric complex (Sterckx et al.,
2016). In typical toxin–antitoxin modules, the antitoxin and
the toxin–antitoxin complex regulate the expression of the
operon. However, PaaA2 does not possess a DNA-binding
domain (Sterckx et al., 2014) and transcription regulation of
the operon requires PaaR2 (Hallez et al., 2010; De Bruyn et al.,
2019). The molecular details of how PaaR2 interacts with its
DNA target and whether this interaction is influenced by
ParE2, PaaA2 or the ParE2–PaaA2 complex remain unclear.
In this paper, we report the expression, purification and
nanobody-assisted crystallization of PaaR2. The resulting
structure is expected to contribute to our understanding of
the regulation of the paaR2–paaA2–parE2 toxin–antitoxin
module.
2. Materials and methods
2.1. Cloning, expression and purification of PaaR2
The cloning and expression of full-length PaaR2 with a
C-terminal His tag and a serine substituted for Cys120 has
been described previously (De Bruyn et al., 2019). The
expression plasmid (pET15bR2HisC120SA2E2) not only
contains the mutated paaR2 gene, but also the coding
sequences for PaaA2 and ParE2. Cloning and production
details are summarized in Table 1. For protein production,
pET15bR2HisC120SA2E2 was transformed into the expres-
sion strain E. coli BL21 (DE3).
A colony of E. coli BL21 (DE3) (pET15bR2HisC120S-
A2E2) was grown overnight at 37C in 300 ml LB medium
supplemented with ampicillin (100 mg ml1). The overnight
culture was diluted 50 times in 12 1 l flasks of LB and grown at
37C with shaking. When the OD600 reached 0.6–0.8, the cells
were induced with 1 mM isopropyl -d-1-thiogalactopyrano-
side (IPTG). After further incubation for 4 h at 37C with
shaking, the cells were pelleted for 13 min at 4C using a
JLA-8.1000 rotor at 5000 rev min1 (6238g). Each pellet was
resuspended in lysis buffer [20 mM Tris–HCl pH 7.3, 500 mM
NaCl, 20 mM MgCl2, 0.1 mg ml
1 4-(2-aminoethyl)benzene-
sulfonyl fluoride hydrochloride (AEBSF), 1 mg ml1 leupeptin,
50 mg ml1 DNase I]. This suspension was then left to stir for
30 min at 4C. Lysis was achieved by sonication three times for
1 min. The lysate was centrifuged for 45 min using a JA-20
rotor at 18 000 rev min1 (39 191g) and was loaded onto a
5 ml HisTrap HP Ni2+-Sepharose column (GE Healthcare)
that had been pre-equilibrated with least one column volume
of buffer A (20 mM Tris–HCl pH 7.3, 500 mM NaCl, 5 mM
imidazole). After a wash period, buffer B (20 mM Tris–HCl
pH 7.3, 500 mMNaCl, 1 M imidazole) was added to generate a
linear gradient of 0–1 M imidazole over 50 column volumes.
The fractions containing the protein of interest, PaaR2, were
pooled and concentrated to a volume of 2 ml.
The Ni–NTA-purified protein was subsequently loaded
onto a Superdex 200 16/90 SEC column (GE Healthcare)
which had been washed and pre-equilibrated with at least one
column volume of SEC buffer (20 mM Tris–HCl pH 7.3,
500 mMNaCl). The eluted samples were checked for purity by
SDS–PAGE and the relevant fractions were pooled, flash-
frozen and stored at 20C.
2.2. Cloning, expression and purification of PaaR21–57 and
PaaR21–66
The plasmid pET15b-PaaR2His-PaaA2-ParE2 was PCR-
amplified, except for the C-terminal end sequence that was
desired to be deleted, using overlapping primers and Q5
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High-Fidelity 2X Master Mix (NEB). Primers PaaR2_7 and
PaaR2_8 were used for the PaaR21–57 truncate and primers
PaaR2_7 and PaaR2_9 for the PaaR21–66 truncate (Table 1).
The final truncates contain a 30-terminal His tag. Following
PCR amplification, unmodified plasmid was degraded by
incubation with DpnI for 1 h at 37C. After confirming the
deletion by sequencing, CaCl2-competent E. coli BL21 Star
(DE3) cells were transformed with the mutated plasmids.
PaaR21–57 and PaaR21–66 were expressed and purified in a
similar way to the full-length protein, except that a Superdex
75 16/60 SEC column (GE Healthcare) column was used in the
polishing SEC step.
2.3. Generation of nanobodies
A set of ten His-tagged nanobodies were generated by
the Nanobodies4Instruct centre (Steyaert laboratory, Vrije
Universiteit Brussel, Brussels, Belgium) following a previously
described protocol (Pardon et al., 2014). In brief, the antigen
(PaaR2) was injected six times into a llama along with the
adjuvant GERBU LQ to stimulate the immune response.
After the immune response, a sample of peripheral blood was
taken containing B-cell lymphocytes. These were used to clone
the affinity-matured nanobodies. cDNAwas synthesized from
B-cell RNA and used for nested PCR before cloning into an
appropriate vector (pMESy4, GenBank KF415192), allowing
release of the nanobodies in the periplasm and providing them
with a C-terminal His tag (Pardon et al., 2014). Panning of the
potential binders to PaaR2 was performed by phage display.
The vector was transformed into E. coli WK6Su cells for
expression.
Cell cultures were grown by inoculating 10 ml preculture in
1000 ml TB medium (12 g tryptone, 24 g yeast extract, 12.55 g
K2HPO4, 2.3 g KH2PO4, 0.4% glycerol in 1000 ml water pH
7.5; Tartof & Hobbs, 1987) supplemented with 100 mg ml1
ampicillin, 0.1%(w/v) glucose and 2 mM MgCl2 and shaken at
37C and 120 rev min1. Expression of the nanobody was
induced by adding 1 mM IPTG at an OD600 of 0.7. After
overnight incubation at 28C with shaking at 120 rev min1,
the cells were collected by centrifugation for 10 min at 4790g
(5000 rev min1 in a JLA-8.1000 rotor). Each pellet was
resuspended in 15 ml cold TES buffer [0.2 M Tris–HCl pH 8,
0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.5 M
sucrose] and left stirring for 1 h at 4C. Next, 30 ml fourfold-
diluted TES buffer was added to each suspension and further
stirred at 4C for 45 min. The periplasmic extract was obtained
by centrifuging the suspension for 30 min at 4790g
(5000 rev min1 in a JLA-8.1000 rotor) and recovering the
supernatant. The nanobodies were purified by IMAC using
Ni2+-Sepharose 6 Fast Flow medium (GE Healthcare),
followed by SEC on an Enrich SEC70 column (Bio-Rad) on
an ÄKTAexplorer platform (GE Healthcare). The Ni2+-
Sepharose medium was first equilibrated with 50 mM phos-
phate pH 7.0, 1 MNaCl and centrifuged for 2 min at 460g. The
periplasmic extract was added to the medium and left to shake
at room temperature for 1 h. The suspension was centrifuged
for 2 min at 460g before loading the beads onto a PD-10
column (GE Healthcare). First, a wash step was performed
using one column volume of 50 mM phosphate pH 7, 1 M
NaCl solution, followed by a second wash step using two
column volumes of 50 mM phosphate pH 6, 1M NaCl. The
nanobody was eluted with one column volume of 50 mM
acetate pH 4.5, 1 MNaCl. Eluted fractions were neutralized in
1 M Tris–HCl pH 7.4 and concentrations were measured using
a Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific). Samples from the flowthrough, the two washing
steps and the eluted fractions were analysed by SDS–PAGE.
The fractions containing the nanobody were concentrated
using Amicon Ultracel-3K filters (molecular-weight cutoff
3.5 kDa; Merck Millipore) for subsequent SEC. The column
methods communications
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Table 1
Macromolecule-production information.
Construct PaaR2HisC120S PaaR21–57 PaaR21–66
Source organism E. coli O157:H7 E. coli O157:H7 E. coli O157:H7
DNA source E. coli O157:H7 PaaR2HisC120S PaaR2HisC120S
Cloning paaR2: forward primer AGGAGATATACCATGCAAAAAAAAGAAATT
CGC (paaR2_1)
— —































Cloning vector pET15b pET15b pET15b
Expression vector pET15b pET15b pET15b
Expression host E. coli BL21 (DE3) E. coli BL21 (DE3) E. coli BL21 (DE3)
Complete amino-acid sequence












was pre-equilibrated with phosphate-buffered saline (PBS;
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4). A 2 ml sample of nanobody in the same buffer was
then injected and eluted at 1 ml min1 with PBS in fractions of
0.5 ml. Fractions from the elution peak were analysed by SDS–
PAGE and were stored at 20C.
2.4. Analytical size-exclusion chromatography
Analytical SEC of the PaaR2 sample was carried out on a
Shodex KW404-4F column equilibrated with 20 mM Tris–HCl
pH 7.3, 500 mM NaCl. The PaaR2 sample was loaded at a
concentration of 1.59 mg ml1 in a volume of 0.5 ml. The
PaaR2–Nb33 sample was prepared by mixing PaaR2 and
Nb33 to final concentrations of 5.4 mg ml1 (PaaR2) and
7.0 mg ml1 (Nb33) in a final volume of 0.2 ml and running on
a Bio-Rad Enrich SEC650 column. In both cases the flow rate
was 1 ml min1.
Analytical SEC for the PaaR2 truncates and Nb33 samples
was carried out on a Superdex Increase 75 column equili-
brated with 20 mM Tris–HCl, 150 mM NaCl pH 7.5. The flow
rate was 0.75 ml min1. For the analytical gel filtration of the
PaaR2 truncates and Nb33 alone and together in a complex,
the injection volume was 250 ml and the concentration was
1 mg ml1. The complexes of the PaaR2 truncates and Nb33
were made by mixing 2 mg PaaR2 truncate with 3.2 mg Nb33
(a 1.2-fold molar excess of Nb33) and were left to incubate at
room temperature for 30 min before injection. For the
analytical gel filtration of PaaR2 truncates alone at higher
concentration, the injection volume was 300 ml and the
concentration was 5 mg ml1. To calibrate the columns, we
used the Bio-Rad Size Exclusion Standard (bovine thyro-
globulin, 670 kDa; bovine -globulin, 158 kDa; chicken oval-
bumin, 44 kDa; horse myoglobin, 17 kDa; vitamin B12,
1.35 kDa). Molecular weights were estimated according to
Whitaker (1963).
2.5. Mass spectrometry
Protein samples for LC-MS/MS mass spectrometry were
reduced by the addition of 5 mMDTT, followed by incubation
for 1 h at 56C. Subsequently, a final concentration of 25 mM
iodoacetamide was added and the samples were incubated for
a further 30 min at room temperature. The proteins were then
digested with mass-spectrometry-grade trypsin (Thermo
Fisher Scientific) at a final concentration of 0.04 mg ml1 for
18 h at 37C. After digestion, the samples were analyzed using
a Q-Exactive Orbitrap (Thermo Fischer Scientific) mass
spectrometer in a shotgun analysis-type experiment following
reverse-phase liquid chromatography.
For native ion-mobility mass-spectrometry experiments,
samples of PaaR2 and of the nanobodies were prepared by
overnight dialysis against 150 mM ammonium acetate buffer
pH 7.3. Complexes were prepared by adding PaaR2 and
nanobody together in equimolar amounts to a final concen-
tration of 20 mM each in 150 mM ammonium acetate buffer
pH 7.3. Using in-house-prepared, gold-coated borosilicate
glass needles, samples were introduced into the mass
spectrometer via nano-electrospray ionization with a spray
voltage of +1.6 kV. Spectra were recorded on a travelling-
wave ion-mobility quadrupole time-of-flight instrument
(Synapt G2 HDMS, Waters, Wilmslow, UK). Critical voltages
throughout the instrument were 40 V for the sampling cone,
1 V for the extraction cone, 10 V trap collision voltage, 45 V
for the trap DC bias and 0.5 V transfer collision voltage.
Pressures throughout the instrument were 6 mbar, 4.3 
102 mbar, 3 mbar and 3.9  102 mbar for the source, trap
collision cell, ion-mobility cell and transfer collision cell,
respectively.
2.6. CD spectroscopy
PaaR21–57 and PaaR21–66 were dialyzed against 10 mM
NaH2PO4, 10 mM Na2HPO4, 150 mM NaCl pH 7.5 with two
buffer changes, the second one overnight, at room tempera-
ture in Slide-A-Lyzer 3.5K Dialysis Cassettes G2 (Thermo
Fischer Scientific). CD measurements were performed on a
Jasco J-1500 spectropolarimeter (Jasco, Japan). Thermal
denaturation was followed by measuring the ellipticity at
222 nm in the temperature range 10–95C every 1C with a
scanning speed of 1C min1. The CD spectra were measured
between 200 and 250 nm with a scanning speed of
20 nm min1 at 25C. The signal was measured every 1 nm,
with a bandwidth of 1 nm and a digital integration time of 4 s.
Protein samples with a concentration of 0.3 mg ml1 were
measured in a quartz cuvette with a path length of 1 mm, while
for samples of 0.03 mg ml1 a quartz cuvette with path length
5 mm was chosen. The acquired data were normalized using






where N is the number of amino-acid residues, c is the molar
concentration and l is the path length. Melting temperatures
were determined by normalizing the signal to obtain the





[N] and [D] are the molar ellipticities of the native and the
unfolded state determined by extrapolating the baseline
before and after the transition.
2.7. Isothermal titration calorimetry
PaaR21–57, PaaR21–66 and Nb33 were dialyzed at room
temperature against 10 mM NaH2PO4, 10 mM Na2HPO4,
0.01% Triton X-100, 150 mM NaCl pH 7.5 with two buffer
changes, the second one overnight, in Slide-A-Lyzer 3.5K
Dialysis Cassettes G2 (Thermo Fisher Scientific). Prior to
measurements, the samples were spun down at
13 300 rev min1 for 10 min and degassed on a degassing
station (TA Instruments) for 30 min. The experiments were
performed on a MicroCal PEAQ-ITC microcalorimeter
(Malvern Panalytical) with 8.7 mM Nb33 in the cell and
methods communications
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74.3 mM PaaR21–57 or 80.0 mM PaaR21–66 in the syringe. For
PaaR21–66 data were measured at 5, 20, 32 and 37C. For
PaaR21–57 no usable heat signal was observed below 20C and
data were measured at 20, 25, 28 and 32C. The heat of dilu-
tion of the PaaR2 truncates was estimated from the measured
heats obtained after saturation of Nb33 and was subtracted
from the titration curves. The data were analyzed with the
MicroCal PEAQ-ITC Analysis Software using a 1:1 binding
model.
2.8. Crystallization of the PaaR2–Nb33 complex
Crystallization screens were set up using (i) PaaR2 (at
concentrations of 6.5, 8 and 10 mg ml1), (ii) PaaR2 with
various nanobodies mixed directly into the crystallization drop
at a 1:1 molar ratio (at complex concentrations of 3.5, 6 and
7 mg ml1) and (iii) a pre-purified PaaR2–Nb33 complex (at
concentrations of 5.5, 6, 7, 8.2 and 11 mg ml1). The buffers
used were 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4 (PBS), 20 mM Tris–HCl pH 7.3, 500 mM
NaCl and 20 mM Tris–HCl pH 7.3, 150 mM NaCl. PaaR2–
Nb33 complexes were prepared in a 1:1.5 ratio and concen-
trated to a volume of 0.5 ml using Amicon 10 kDa centrifugal
filters. SEC was performed using a Bio-Rad Enrich SEC650
column which was pre-equilibrated in 20 mM Tris–HCl pH 7.3,
500 mM NaCl. The relevant fractions were pooled and the
protein complex was concentrated using an Amicon Ultra 10K
molecular-weight cutoff centrifugal filter.
Crystallization conditions were screened at 20 and 4C by
the hanging-drop and sitting-drop vapour-diffusion methods
using Hampton Research VDX 48-well and Intelli-Plate 96-3
LVR plates or SWISSCI MRC crystallization plates. Hanging
drops consisted of 1 ml protein solution (2  0.5 ml if PaaR2
and the nanobody were added separately) and 1 ml reservoir
(or seeds in reservoir solution) and were equilibrated against
170 ml reservoir solution. Sitting drops consisted of 0.1 ml
PaaR2–Nb33 solution and 0.1 ml reservoir solution and were
equilibrated against 70 ml reservoir solution. Crystallization
conditions were tested with several commercially available
screens: Crystal Screen, Crystal Screen 2 and PEGRx
(Hampton Research), ProPlex and JCSG-plus (Molecular
Dimensions).
2.9. Crystallization of PaaR21–57 and PaaR21–66 in complex
with Nb33
For PaaR21–57 and PaaR21–66 and their purified complexes
with Nb33, crystallization conditions were screened by the
sitting-drop method using Intelli-Plate 96-3 LVR plates
(Hampton Research) and a Mosquito Crystallization Robot
(TTP Labtech). The complexes between the PaaR2 truncates
and Nb33 were prepared by mixing the proteins together in a
1:1 molar ratio. After 30 min incubation at room temperature
the complexes were purified on a Bio-Rad Enrich SEC70
column. The protein concentrations used for crystallization
screening ranged from 10 to 70 mg ml1. In each case, 100 nl
protein solution (in 20 mM Tris, 150 mM NaCl pH 7.5) was
mixed with 100 nl reservoir solution and equilibrated at 19C
against 70 ml reservoir solution from various commercial
crystallization kits (Crystal Screen and Crystal Screen 2 from
Hampton Research and JSCG-plus, PACT premier and
Morpheus from Molecular Dimensions).
2.10. X-ray data collection and analysis
Crystals were flash-cooled in liquid nitrogen after trans-
ferring them to a suitable cryoprotectant solution (glycerol,
PEG 400 and ethylene glycol were tried). X-ray data were
measured on the PROXIMA-1 and PROXIMA-2A beamlines
at the SOLEIL synchrotron facility (Gif-sur-Yvette, France)
and recorded on an EIGER X 9M photon-counting area
detector. Data were indexed, integrated and scaled with XDS
(Kabsch, 2010) via theXDSME interface. The Laue group and
space group were further verified, and potential twinning was
assessed with phenix.xtriage (Zwart et al., 2005) and POINT-
LESS (Evans, 2006). The likely unit-cell content was estimated
using the CCP4 program MATTHEWS_COEF (Kantardjieff
& Rupp, 2003). Data-collection statistics are summarized in
Table 2.
3. Results and discussion
3.1. Production and characterization of PaaR2
Our initial construct consisted of the coding regions for
the wild-type paaR2–paaA2–parE2 operon. The presence of
paaA2–parE2 in this construct was motivated by our previous
observations that the transformation of a plasmid encoding
PaaR2 in the absence of PaaA2 and ParE2 is toxic to E. coli.
The produced protein showed a tendency towards aggrega-
tion. We reasoned that this could be caused by the presence of
the single cysteine at position 120. We therefore constructed
the C120S mutant (De Bruyn et al., 2019). PaaR2 with a
hexahistidine tag at its C-terminus and including the mutation
C120S was overexpressed in E. coli BL21 (DE3) cells and
purified to homogeneity (Supplementary Fig. S1). The protein
shows a single band corresponding to the correct molecular
weight on SDS–PAGE. The identity of the purified protein
was confirmed by LC-MS/MS mass spectrometry. The
experimentally determined value of 15 295.4  2.0 Da corre-
sponds to the theoretical value of 15 296.3 Da. The yields that
have been obtained in repeated purifications are between 3
and 4 mg per litre of culture medium. We previously showed
that this protein forms a well folded, stable octamer and binds
specifically to its operator region (De Bruyn et al., 2019).
Crystallization conditions were initially screened using this
PaaR2 preparation, but did not lead to any crystallization hits.
3.2. Nanobodies against PaaR2
After attempts to crystallize PaaR2 on its own failed, we
raised nanobodies against PaaR2 for use as crystallization
chaperones. Panning of the potential binders to PaaR2 by
phage display resulted in ten nanobodies with unique CDR3
sequences that could be overexpressed and purified (Fig. 1).
We initially tried to preform and purify PaaR2–nanobody
complexes using SEC. Addition of each nanobody to the
methods communications
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PaaR2 solution led to visible precipitation under all conditions
tried. Equally, attempts to co-crystallize PaaR2 and the
different nanobodies by mixing the components directly in the
crystallization drops also resulted in heavy precipitation and a
failure to produce crystals.
This nanobody-induced precipitation was unexpected, and
we reasoned that perhaps our nanobodies interfered with the
correct oligomerization of PaaR2. When injected into the
bloodstream of the llama, PaaR2 becomes diluted and the
oligomeric state that is observed at higher concentrations in
the test tube may partially or fully dissociate, presenting
otherwise hidden surfaces to the immune system. Nanobodies
interacting with such surfaces may then induce aggregation at
higher protein concentrations due to incorrect oligomeriza-
tion. Based on this hypothesis, we decided to screen our
nanobodies for interaction with the PaaR2 oligomer using
native mass spectrometry.
In agreement with our earlier work (De Bruyn et al., 2019),
the native mass spectrum of PaaR2 shows a single, compact
charge-state distribution (Fig. 2a), which is characteristic of a
well folded protein complex with little to no significant
structural disorder (Konijnenberg et al., 2013; Testa et al., 2011,
2013). The corresponding mass of 122 780 Da agrees closely
with the theoretical value of 122 370.4 Da for an octameric
assembly of PaaR2.
The overall majority of the nanobodies displayed a rather
poor binding profile in these experiments, as demonstrated by
large remaining populations of free nanobody monomers and
small complex populations, as shown for nanobody 14 in
Fig. 2(b). In contrast, the mass spectrum of PaaR2 in the
presence of nanobody 33 (Nb33) showed a large population of
PaaR2 octamers with eight nanobodies bound (Fig. 2c). The
spectrum of the PaaR2–Nb33 mixture contains virtually no
free nanobody, suggesting that Nb33 has a high affinity for
octameric PaaR2. The m/z ratio associated with the largest
population in the mass spectrum indeed corresponds to a
heterohexadecamer (PaaR28–Nb338) with a molecular mass of
228 kDa. We therefore decided to continue only with Nb33.
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Figure 1
Nanobody sequences. A BLAST alignment of the ten nanobody sequences that were initially identified as binders and used in further experiments is
shown. CDR regions are boxed.
Table 2
Data collection and processing.
Values in parentheses are for the outer shell.
PaaR2–Nb33 PaaR21–57–Nb33 PaaR21–66–Nb33
Diffraction source SOLEIL SOLEIL SOLEIL
Beamline PROXIMA-2A PROXIMA-1 PROXIMA-1
Wavelength (Å) 0.980 0.979 0.979
Temperature (K) 100 100 100
Detector EIGER X 9M EIGER X 9M EIGER X 9M
Crystal-to-detector distance (mm) 465.2 242.5 204.8
Rotation range per image () 0.1 0.1 0.1
Total rotation range () 360 360 360
Space group F432 P212121 P3121 or P3221
a, b, c (Å) 316.7, 316.7, 316.7 45.6, 56.6, 128.3 67.1, 67.1, 69.7
, ,  () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0
Overall B factor from Wilson plot (Å2) 138.2 25.4 34.0
Mosaicity () 0.047 0.185 0.123
Resolution range (Å) 48.3–3.95 (48.3–11.54/4.01–3.95)† 64.1–1.60 (1.69–1.60) 44.6–1.75 (1.86–1.75)
Total No. of measured reflections 926178 (52510/142494) 564735 (69688) 371769 (55088)
No. of unique reflections 12488 (910/1936) 44565 (6812) 18776 (2991)
Completeness (%) 99.8 (100.0/99.5) 99.2 (95.1) 99.8 (99.0)
Multiplicity 74.2 (57.8/73.6) 12.7 (10.2) 7.75 (6.28)
hI/(I)i 10.5 (36.6/0.89) 19.0 (1.32) 25.0 (0.85)
Rmerge 0.462 (0.073/2.926) 0.066 (1.161) 0.054 (3.543)
Rmeas 0.466 (0.074/2.946) 0.069 (1.221) 0.056 (3.641)
CC1/2 0.999 (1.000/0.534) 0.999 (0.565) 0.999 (0.589)
† Because of the high overall value of Rmerge we also provide statistics for the inner data shell to show that Rmerge is small and compatible with the high hI/(I)i, and that the high Rmerge is
not a consequence of imposing too high a symmetry. Reprocessing in lower symmetry does not significantly change the Rmerge values.
3.3. Nanobody-assisted crystallization of PaaR2
Surprisingly, even Nb33 produced complexes with low
solubility and precipitated at low ionic strength (150 mM
NaCl). We therefore initially screened for crystallization
conditions by mixing two separate stock solutions of PaaR2
and Nb33 in equimolar amounts directly in the drop with the
precipitant solution. This strategy resulted in a hit condition
when transferring the crystallization plate from 20 to 4C, but
did not result in diffracting crystals (Fig. 3a).
We subsequently discovered that the PaaR2–Nb33 complex
is soluble at high ionic strength (500 mM NaCl) and room
temperature, and that under such conditions the complex can
be purified by SEC and concentrated to 11 mg ml1 (Fig. 4a).
This preparation was used to set up new crystallization
screens, leading to a hit in 0.1 M sodium acetate trihydrate pH
4.6, 2.0 M sodium formate (Fig. 3b). Variation of the pH and
precipitant concentration did not result in visual improvement
of the crystals, but seeding ultimately led to large three-
dimensional crystals in the original hit condition (Fig. 3c).
Crystallization only occurred after incubating the complex for
2 h at 4C, which induces precipitation that is reversible when
the sample is moved to 20C. In order to confirm the presence
of both PaaR2 and Nb33, crystals were harvested, washed in
artificial mother liquor and subsequently analysed by SDS–
PAGE (Fig. 4a, inset). This analysis showed that the crystals
contained both proteins in an apparently equal stoichiometry,
similar to the isolated PaaR2–Nb33 complex.
Three cryoprotectants were tested using the mother liquor
supplemented with 30% glycerol, 20% PEG 400 or 25%
ethylene glycol. Crystals were tested on the PROXIMA-2A
beamline at the SOLEIL synchrotron, Gif-Sur-Yvette, France
and showed variable diffraction that was usually limited to 5–
4.5 Å resolution, but always with sharp, well separated spots
(Fig. 3d). The best diffraction was obtained from a crystal
cryoprotected with 30% glycerol and provided useful data to a
resolution of 4.0 Å (Fig. 3d). The crystals belonged to space
group F432, with unit-cell parameter a = 317 Å (Table 2).
While the Rmerge and Rmeas values are very high, they result
from a large amount of very weak data with very high (74-
fold) multiplicity. Both Rmerge and Rmeas increase steadily with
resolution starting from reasonably low values (0.073 and
0.074, respectively) up to almost 3.00. The high-resolution
cutoff was determined using CC1/2 (Karplus & Diederichs,
2012) and I/(I) dropping below 1.0, and will have to be fine-
tuned during the structure-solution and refinement process.
Nevertheless, we are confident that these data are valid, that
the extremely high multiplicity allows the otherwise very weak
data to be used to around 4 Å resolution and that the Rmerge
and Rmeas values are therefore not informative. Matthews
analysis (Matthews, 1968) suggests that the asymmetric unit is
likely to contain four PaaR2 monomers and four Nb33
monomers.
3.4. Crystallization of PaaR2 truncates
In order to obtain higher resolution data, we constructed two
PaaR2 truncates, PaaR21–57 and PaaR21–66, comprising the
N-terminal HTH domain. Both truncates could be expressed
at high levels (15 mg per litre of bacterial culture) in E. coli
BL21, are highly soluble (can be concentrated to greater than
100 mg ml1) and behave as monomers in solution (Fig. 5a;
Supplementary Fig. S2). The latter result indicates that the
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Figure 2
Native mass spectrometry. (a) Native mass spectrum of pure PaaR2. The
spectrum mainly contains peaks corresponding to an octamer, with
additional traces of a tetramer and a dimer. (b) In the presence of an
excess of Nb14, the PaaR2 octamer remains present, and only traces of a
PaaR28–Nb14 species are observed next to large amounts of free
nanobody. Similar results were obtained for other nanobodies. (c) In the
presence of Nb33, the major species becomes a PaaR28-Nb338 complex,
with very little if any free nanobody or free PaaR2.
C-terminal region, which is predicted to form a coiled-coil
structure, is responsible for oligomerization. The CD spectra
of the truncates indicate that they are both folded and adopt a
mainly -helical structure (Fig. 5b). A concentration-
independent melting temperatures of 53.7C was obtained for
PaaR21–57. For PaaR21–66, the melting temperature varies with
concentration: 71.2C at 0.03 mg ml1 and 73.8C at 0.3 mg ml1
(Fig. 5c). The latter is unexpected for a monomeric protein
and suggests that PaaR21–66 may have a weak tendency
towards oligomerization, although this was not detected in the
analytical SEC experiment. The large difference in melting
temperature between PaaR21–57 and PaaR21–66 further indi-
cates that residues 58–66 significantly contribute to stability.
As for full-length PaaR2, no crystals were obtained for
PaaR21–57 and PaaR21–66 alone. We therefore tested the
abilities of PaaR21–57 and PaaR21–66 to bind Nb33. The
analytical SEC profiles of the PaaR2 truncates mixed together
with Nb33 show a peak eluting around apparent molecular
weights of 15.2 and 18.5 kDa for PaaR21–57 and PaaR21–66,
respectively, distinct from the elution peaks of either the
truncate or the nanobody in isolation, indicating that Nb33
indeed binds PaaR2 truncates (Figs. 4b and 4c). The latter was
confirmed using isothermal titration calorimetry (Fig. 6). For
both PaaR21–57 and PaaR21–66 the reaction is exothermic at
temperatures of 20C or higher. Binding is endothermic at 5C
for PaaR21–66 but could not be measured for PaaR21–57. The
resulting thermodynamic parameters are given in Table 3. The
heat signals are very low and no reliable thermodynamic
parameters could be extracted for PaaR21–57 at 5C. The data
were interpreted using a 1:1 binding model in each case. The
derived affinities range between 0.517 and 19.1 nM, with the
differences between PaaR21–57 and PaaR21–66 being small.
However, tight binding combined with the small amounts of
heat produced puts significant errors on the dissociation
constants (Kd). Affinities decrease with increasing tempera-
ture. For both of the truncates the binding Gibbs energy (G)
is favourable and does not show significant temperature
dependence due to the compensating contributions of binding
enthalpy (H) and entropy (S). With increasing tempera-
ture the binding becomes more enthalpy-driven, while at
lower temperatures it becomes more entropy-driven. The
determined binding Gibbs energies at 25C for PaaR21–57 and
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Figure 3
Crystals of the PaaR28–Nb338 complex. (a) Initial hit obtained by mixing PaaR2 and Nb33 in an equimolar ratio directly in the drops at low ionic
strength (150 mMNaCl). These crystals did not show diffraction. (b) Shower of microcrystals obtained at 4C using pre-purified PaaR28–Nb338 complex
at high ionic strength (500 mMNaCl). The scale is identical to that in (a). (c) Crystals after optimization using seeding of the hit shown in (b). The scale is
identical to that in (a). (d) Diffraction pattern obtained from a crystal similar to those shown in (c). (e) Crystal of the PaaR21–57–Nb33 complex used for
data collection. ( f ) Crystal of the PaaR21–66–Nb33 complex used for data collection.
PaaR21–66 are 10.9 and 11.9 kcal mol1, respectively. The
heat capacity change of binding (Cp), determined from the
linear regression of binding enthalpy versus temperature, is
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Figure 4
Preparation of the complexes with Nb33. (a) Analytical SEC profile of
PaaR2 (5.4 mg ml1 final concentration) mixed with a 1.5-fold molar
excess of Nb33 (7.0 mg ml1 final concentration) and injected onto a Bio-
Rad Enrich SEC650 column. Peak 1 corresponds to the complex, while
peak 2 corresponds to excess nanobody. The inset shows an SDS–PAGE
analysis of the peaks derived from the chromatogram in (a). Lane M
corresponds to the molecular-weight marker, while lane C corresponds to
washed and dissolved crystals of the PaaR28–Nb338 complex. (b)
Analytical SEC profiles of the PaaR21–57–Nb33 complex prepared using
an excess of Nb33 (green) overlaid on the corresponding profiles of
PaaR21–57 (blue) and Nb33 (black). (b) Analytical SEC profiles of the
PaaR21–66–Nb33 complex prepared using an excess of Nb33 (green)
overlaid on the corresponding profiles of PaaR21–57 (red) and Nb33
(black).
Figure 5
Biophysical characterization of PaaR21–57 and PaaR21–66. (a) Analytical
SEC profiles of PaaR21–57 (blue) and PaaR21–66 (red) at 5 mg ml1. The
elution volumes of the molecular-weight standards (bovine -globulin,
158 000 Da; chicken ovalbumin, 44 000 Da; horse myoglobin, 17 000 Da;
vitamin B12, 1350 Da) are plotted as white squares. The elution volumes
of PaaR21–57 (marked as a red square) and PaaR21–66 (blue square) give
molecular-weight estimates of 4.8 and 6.7 kDa, respectively. (b) CD
spectra of PaaR21–57 (blue) and PaaR21–66 (red) measured at 25C at a
concentration of 0.3 mg ml1. (c) Thermal unfolding of PaaR21–57 (blue)
and PaaR21–66 (red) followed by CD spectroscopy at 222 nm and
0.3 mg ml1 (triangles) or 0.03 mg ml1 (circles).
negative: 565 cal mol1 K1 for PaaR21–57 and
438 cal mol1 K1 for PaaR21–66.
Screening of crystallization conditions yielded a single
condition for each complex that resulted in large, well
diffracting crystals (Figs. 3e and 4f). The PaaR21–57–Nb33
complex crystallized at 38.48 mg ml1 in 0.2 M sodium iodide,
20% PEG 3350, while the PaaR21–66–Nb33 complex crystal-
lized at 60.42 mg ml1 in 0.02 M sodium/potassium phosphate,
20% PEG 3350. Crystals of the PaaR21–57–Nb33 complex
diffracted to 1.6 Å resolution and belonged to space group
P212121, with unit-cell parameters a = 45.6, b= 56.6, c= 128.3 Å.
Full details of data collection are given in Table 2. Matthews
analysis suggests the presence of two complexes in the
asymmetric unit, with a solvent content of 37% (VM =
1.95 Å3 Da1).
Crystals of the PaaR21–66–Nb33 complex diffracted to
1.75 Å resolution and belonged to space group P3121 or
P3221, with unit-cell parameters a = b = 67.1, c = 69.7 Å. Full
details of data collection are given in Table 2. Matthews
analysis indicates the presence of a single copy of the complex
in the asymmetric unit, with a solvent content of 41% (VM =
2.05 Å3 Da1).
4. Conclusion
We have expressed and purified the transcription regulator
PaaR2 from the E. coli O157:H7 three-component toxin–
antitoxin system paaR2–paaA2–parE2. Nanobodies were
produced to use as crystallization chaperones for PaaR2. Via
native mass spectrometry, various nanobodies were screened
to find those that recognize and stabilize this oligomeric state.
While most nanobodies either caused the protein solution to
precipitate or resulted in too much free nanobody and PaaR2
complex, one nanobody was found that stabilized the octa-
meric complex and forms a heterohexadecameric complex
with PaaR2. This nanobody was successfully used as a crys-
tallization chaperone for PaaR2. The same nanobody also
allowed the crystallization of the monomeric N-terminal
domain of PaaR2. The latter crystals diffracted to high reso-
lution and are suitable for structure determination. The
structures of PaaR21–57 and PaaR21–66 bound to Nb33 will be
determined by molecular replacement using a nanobody
structure stripped of the CDR loops as a search model. The
structures of the resulting complexes can then be used as
search models to determine the structure of full-length PaaR2
in complex with Nb33.
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Figure 6
ITC titrations of Nb33 against PaaR21–57 and PaaR21–66. (a) Titrations of
PaaR21–57 at four different temperatures. Integrated heats of binding per
mole of injectant versus molar ratio ([syringe]/[cell]) for each titration




















PaaR21–57 20 8.7 74.3 4579 0.868 1.9 11.7 4.23 7.48 565
PaaR21–57 25 8.7 74.3 837 0.857 10.4 10.9 7.14 3.75
PaaR21–57 28 8.7 74.3 503 0.943 17.3 10.7 8.19 2.52
PaaR21–57 32 8.7 74.3 455 0.897 19.1 10.8 11.2 0.389
PaaR21–66 5 8.7 80.0 16828 0.862 0.517 11.8 5.35 17.2 438
PaaR21–66 25 8.7 80.0 4860 0.818 1.79 11.9 3.98 7.97
PaaR21–66 32 8.7 80.0 861 0.880 10.1 11.2 6.69 4.48
PaaR21–66 37 8.7 80.0 1073 0.852 8.11 11.5 8.52 2.96
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